CD19 CAR-T Therapy for Patients With Newly Diagnosed High-risk Large B-cell Lymphoma

This trial tests whether CD19 CAR-T cell therapy — a type of genetically engineered immune cell treatment — can work as a first-line option for people with newly diagnosed aggressive B-cell lymphoma who are unwilling to receive standard RCHOP chemotherapy. **You may be eligible if...** - You are 18 or older with newly diagnosed aggressive B-cell lymphoma (such as DLBCL or high-grade B-cell lymphoma) - You are unwilling to receive standard RCHOP chemotherapy but are willing to receive a short pre-conditioning drug regimen instead - After two courses of pre-conditioning therapy, your cancer showed partial response or stable disease on PET-CT - Your heart, liver, and kidney function are within acceptable ranges - Your ECOG performance status is 0–2 **You may NOT be eligible if...** - You have a history of brain injury, stroke, epilepsy, or serious heart rhythm problems - You have active hepatitis B, hepatitis C, or HIV - You have previously received any CAR-T or genetically modified T-cell therapy - You are pregnant or breastfeeding Talk to your doctor to see if this trial is right for you.